Seven patents currently held, every record listed here
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Jul 2030
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2015 to 2043.20212027203320392043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2032 · High confidence
Also notable
Ends May 2035 · High confidence
Also notable
Ends Nov 2041 · Medium confidence
Diamino Heterocyclic Carboxamide Compound
US 8,969,336
The most cited patent in this portfolio, cited by 81 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2032.
Pyridine Derivative
US 10,421,762
Granted 2019. Computed term ends 2035.
Heteroaryl Carboxamide Compound
US 12,655,122
Granted 2026. Too new for citation comparison; protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends May 2043 · High confidence
Granted 2026. Too new for citation comparison; protection runs to 2043.
now held by Tenvie Therapeutics, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 24, 2027The maintenance fee for Pyridine Derivative (US 10,421,762) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Heteroaryl Carboxamide Compound | 2 in force | to Nov 2041 |
| Pyridine Derivative | 2 in force | to May 2035 |
| Diamino Heterocyclic Carboxamide Compound | 2 in force | to Nov 2032 |
| Pyridazinyl-Thiazolecarboxamide Compound | 1 in force | to Jan 2043 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,487,491 | Diamino Heterocyclic Carboxamide Compound In force · High confidence | In force | High confidence | |
| US 8,969,336 | Diamino Heterocyclic Carboxamide Compound In force · High confidence | In force | High confidence | |
| US 10,421,762 | Pyridine Derivative held by Astellas Pharma Inc. In force · High confidence | In force | High confidence | |
| US 10,975,091 | Pyridine Derivative held by Astellas Pharma Inc. In force · High confidence | In force | High confidence | |
| US 12,077,519 | Heteroaryl Carboxamide Compound In force · Low confidence | In force | Low confidence | |
| US 12,655,122 | Heteroaryl Carboxamide Compound In force · Medium confidence | In force | Medium confidence | |
| US 12,227,517 | Pyridazinyl-Thiazolecarboxamide Compound In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 1 patent in force now held by others · 18 patents ended · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.